From January 1 to 15, 2026, 11 new cosmetic ingredients (NCIs) have completed notifications with China's National Medical Products Administration (NMPA).
The technical requirements for the 11 NCIs mentioned above have not been disclosed, and they have not yet entered the safety monitoring period. Of these, seven are botanical extracts, while the others include peptides, fermented ingredients, and biosynthesized ingredients.
Ganoderma leucocontextum, primarily found on the Qinghai–Tibet Plateau, was identified as a new Ganoderma species in 2015, named for its characteristic white flesh. Recent studies have advanced understanding of its chemical composition and pharmacological properties.
The Notifer is a wholly-owned subsidiary of Shanghai Jahwa United Co., Ltd., was established in 2003 and serves as a core force for cosmetic ingredient R&D within Shanghai Jahwa. Founded in 1898 and listed in 2001, Shanghai Jahwa is a major Chinese cosmetics company known for brands like Herborist, Six God, and Dr. Yu, and has been actively investing in innovative ingredients and biotech-based skincare solutions.
At the beginning of 2026, Lan Divine completed the notification of two NCIs: Naematelia aurantialba Fruiting Body Extract and Dictyophora rubrovolvata Extract.
To date, LAN DIVINE has notified 5 new cosmetic ingredients, including this one—all of which are plant extracts. In addition, the company registered one NCI in October 2025: Anse® LuoshenZhu. It is the first NCI notified by a Chinese company under the current regulatory framework, and also the first colorant to complete registration.
Botanee Group, established in 2010, is a leading player in China’s health industry and the parent company of WINONA, a well-known skincare brand specializing in sensitive skin. As of January 15, 2026, the company has notified 18 new cosmetic ingredients, all derived from botanical sources.
Notably, the notifier of Notification No. 20260011, Nuowaitai (Kunming) Biotechnology Co., Ltd., is a subsidiary of Botanee Group.
Wenzhou Gumor Biotechnology Co., Ltd., established in 2015, is a provincial-level technology-based SME specializing in the research, development, and production of traditional Chinese medicine extracts and cosmetic ingredients. The company focuses on the application of herbal extraction and biofermentation technologies in cosmetics. With this latest two notifications in January 2026, Gumor has completed notifications for a total of five NCIs.
The high number of NCI notifications in the first half of January 2026 suggests a strong start for the year. The continued dominance of botanical ingredients, alongside the growing presence of peptides, fermentation-based, and biosynthesized materials, indicates that China's cosmetic ingredient innovation is evolving in parallel with global R&D trends.
Looking ahead, sustained regulatory clarity, supportive innovation policies, and increasing alignment with international technical standards are expected to further encourage ingredient development and filing activities throughout 2026. The pace observed at the beginning of the year may set the tone for another active year in China's cosmetic ingredient innovation landscape.
